Tenax Therapeutics Liabilities 2024

Tenax Therapeutics Aktienanalyse

What does Tenax Therapeutics do?

Tenax Therapeutics Inc. is a biopharmaceutical company based in Morrisville, North Carolina. It specializes in the development of therapeutics for cardiovascular and pulmonary diseases. The company was founded in 1967 by a group of physicians and scientists. Formerly known as Oxygen Biotherapeutics, it was rebranded as Tenax Therapeutics in 2014. Tenax Therapeutics' business model is focused on the development, manufacturing, and marketing of products for rare diseases. The company aims to develop innovative therapies for severe and life-threatening diseases where there is a high demand for novel treatment options. The focus of Tenax Therapeutics is on cardiovascular and respiratory diseases. The company specializes in the development of medications for the treatment of severe or life-threatening conditions such as cardiogenic shock, pulmonary hypertension, and pulmonary embolism. Over the years, Tenax Therapeutics has established several divisions to streamline its research and development activities. One of the key divisions is clinical research, where the company conducts clinical trials to test the efficacy and safety of its products and obtain regulatory approval. Another pillar of the company is product development, where Tenax Therapeutics develops new compounds and medications to specifically target conditions like cardiogenic shock. Given the high demand for new therapies for rare diseases, the company adopts a highly focused approach and concentrates on developing products for specific indications. Tenax Therapeutics' extensive product portfolio includes various medications and therapeutics that can be used to treat cardiovascular and pulmonary diseases. One important representative in this area is Levosimendan, a vasodilator and inotropic medication used in patients with cardiogenic shock, as well as heart failure and other cardiovascular conditions. Another product in Tenax Therapeutics' portfolio is the active substance ANX-188. This medication is used for the treatment of patients with severe cardiogenic shock and has already been tested in clinical trials. Overall, Tenax Therapeutics aims to develop innovative and effective therapies for rare diseases of the cardiovascular and pulmonary systems. The company strives to address the medical need in this field and ensure high patient satisfaction. Tenax Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Tenax Therapeutics's Liabilities

Tenax Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Tenax Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Tenax Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Tenax Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Tenax Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Tenax Therapeutics stock

What is the level of liabilities of Tenax Therapeutics this year?

Tenax Therapeutics has a debt balance of 3.59 M USD this year.

What were the liabilities of Tenax Therapeutics compared to the previous year?

The liabilities of Tenax Therapeutics have increased by 87.6% increased compared to the previous year.

What are the consequences of high debt for investors of Tenax Therapeutics?

High liabilities can pose a risk for investors of Tenax Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Tenax Therapeutics?

Low liabilities mean that Tenax Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Tenax Therapeutics affect the company?

An increase in liabilities of Tenax Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Tenax Therapeutics affect the company?

A decrease in the liabilities of Tenax Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Tenax Therapeutics?

Some factors that can influence the liabilities of Tenax Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Tenax Therapeutics so important for investors?

The liabilities of Tenax Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Tenax Therapeutics take to modify the liabilities?

To change its liabilities, Tenax Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Tenax Therapeutics pay?

Over the past 12 months, Tenax Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tenax Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Tenax Therapeutics?

The current dividend yield of Tenax Therapeutics is .

When does Tenax Therapeutics pay dividends?

Tenax Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tenax Therapeutics?

Tenax Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Tenax Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tenax Therapeutics located?

Tenax Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tenax Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tenax Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Tenax Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Tenax Therapeutics in the year 2023?

In the year 2023, Tenax Therapeutics distributed 0 USD as dividends.

In which currency does Tenax Therapeutics pay out the dividend?

The dividends of Tenax Therapeutics are distributed in USD.